This is a routine CFO transition with no red flags. Monitor the next 10-Q for any signs of financial reporting delays or control weaknesses, but no immediate trading action is warranted.
Price Chart
Executive Summary
Telomir Pharmaceuticals disclosed the departure of CFO Alan Weichselbaum and the appointment of Andriy Mushak as fractional CFO via a consulting agreement with LMAM Consulting Group, LLC. The change is routine, with no disagreement cited, and the new CFO will be paid $6,000 per month. This is a standard officer transition for a small-cap pharma company with no material financial impact.
Key Facts
- Alan Weichselbaum ceased serving as CFO effective June 6, 2026; departure not due to any disagreement with the company.
- Andriy Mushak, CPA, appointed as fractional CFO effective June 6, 2026, via a consulting agreement with LMAM Consulting Group, LLC.
- Mushak will be paid $6,000 per month for his services.
- Mushak has over 20 years of experience in SEC reporting, accounting compliance, and financial statement audits.
- No family relationships or material interests in transactions requiring disclosure were reported.
Financial Impact
Monthly cash compensation of $6,000 — immaterial relative to the company's $83M market cap.
Risk Factors
- Fractional CFO arrangement may signal limited internal finance resources at a small-cap company.
- No equity incentive disclosed for the new CFO, which could affect retention.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-027752 |
| Document: form8-k.htm | 0001493152-26-027752 |
| Document: 0001493152-26-027752-index-headers.html | 0001493152-26-027752 |
| Document: 0001493152-26-027752-index.html | 0001493152-26-027752 |
| Document: 0001493152-26-027752.txt | 0001493152-26-027752 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 8-K | $1.20 | awaiting T+20 | — | $1.05 (−12.50%) |
Sep 17, 2026 5w ago | 8-K | $1.12 $1.05 | ▼ −6.25% | ▼ −7.46% | $1.05 (−6.25%) |
Sep 17, 2026 5w ago | Press Release | $1.12 $1.05 | ▼ −6.25% | ▼ −7.71% | $1.05 (−6.25%) |
Sep 14, 2026 6w ago | 8-K | $1.17 $1.10 | ▼ −5.98% | ▼ −8.25% | $1.05 (−10.26%) |
Aug 19, 2026 9w ago | DEFA14A | $1.17 $1.12 | ▼ −4.27% | ▼ −2.32% | $1.05 (−10.26%) |
Aug 10, 2026 11w ago | 8-K | $1.17 $1.19 | ▲ +1.71% | ▲ +2.62% | $1.05 (−10.26%) |
Jun 15, 2026 19w ago | 8-K | $1.29 $1.24 | ▼ −3.88% | ▼ −3.13% | $1.05 (−18.60%) |
Jun 8, 2026 20w ago | 8-K | $1.21 $1.24 | ▲ +2.48% | ▲ +1.03% | $1.05 (−13.22%) |
Apr 24, 2026 26w ago | 8-K | $1.40 $1.30 | ▼ −7.14% | ▼ −11.17% | $1.05 (−25.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers